KNX-100 is under clinical development by Kinoxis Therapeutics and currently in Phase II for Unspecified Psychiatric Disorders. According to GlobalData, Phase II drugs for Unspecified Psychiatric Disorders have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KNX-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KNX-100 overview
KNX-100 is under development for the treatment of alcohol addiction, drug (methamphetamine, cocaine and opioid) addiction, aggression and agitation in dementia. It is administered through oral route. The drug candidate targets non-peptide oxytocin receptor (OTR).
Kinoxis Therapeutics overview
Kinoxis Therapeutics (Kinoxis) is a clinical-stage biotechnology company. The company develops a variety of novel therapeutic small-molecule compounds for the treatment of neurological and psychiatric disorders. Its product pipeline includes KNX100, a small molecule therapeutic drug candidate used for the treatment of opioid withdrawal; KNX200 which treats schizophrenia, autism spectrum disorder, social anxiety disorder. The company’s therapeutic areas include autism spectrum disorder, social anxiety disorder, substance use disorder, post-traumatic stress disorder, schizophrenia, depression, and dementia, among others. Kinoxis is headquartered in Melbourne, Victoria, Australia.
For a complete picture of KNX-100’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
